Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer. The study will be carried out in 10 clinical centers in the US.

25 Mar 2011

KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced treatment of the first patient in a Phase 1 clinical trial of KB004, its first-in-class Humaneered™ monoclonal antibody, in EphA3-expressing hematologic malignancies.

24 Mar 2011

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.

21 Mar 2011

Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today the dosing of the first subject in a Phase 2 study with an experimental oral parathyroid hormone analog for the treatment of osteoporosis in postmenopausal women.

16 Mar 2011

Anavex to commence phase I clinical trial in Alzheimer’s disease

Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.

15 Mar 2011

Arena fourth quarter net loss decreases to $28.2 million

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2010, and reviewed recent developments.

11 Mar 2011

Inhibitex fourth quarter net loss increases to $7.0 million

Inhibitex, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2010, and provided an update on recent clinical and corporate developments.

11 Mar 2011

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.

10 Mar 2011

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Vertex Pharmaceuticals Incorporated announced today that 15 abstracts on the company's medicines in development for hepatitis C, including its protease inhibitor, telaprevir, and polymerase inhibitor, VX-222, were accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver in Berlin, Germany, March 30 to April 3, 2011.

9 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

NorthShore receives $1.5 million gift to establish center for the study of complex diseases

NorthShore University HealthSystem (NorthShore) Foundation has received a $1.5 million gift for the creation of the Center for the Study of Complex Diseases. The development of the Center, which is being established within the NorthShore Research Institute, is made possible through a generous gift by Mr. and Mrs. Richard L. Keyser of Glencoe, Ill., through the Keyser Family Research Fund.

4 Mar 2011

Cancer patients' willingness to undergo tests bodes well for future of personalized medicine

Cancer patients are willing to undergo many tests to receive advanced experimental treatment in clinical trials, according to a new study by Mayo Clinic, Scottsdale Healthcare and the Translational Genomics Research Institute.

4 Mar 2011

EC grants marketing authorization for InterMune's Esbriet to treat IPF

InterMune, Inc. today announced that the European Commission has granted marketing authorization for Esbriet. Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis, a progressive and fatal lung disease.

3 Mar 2011

Oxygen Biotherapeutics receives U.S. Army grant for studies of Oxycyte

Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXBT) today announced it has received a $2,075 million two-year grant from the U.S. Army to study the Company’s proprietary Oxycyte® PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury (TBI).

2 Mar 2011

U.S. Army awards Oxygen Biotherapeutics two-year grant to study Oxycyte PFC emulsion against TBI

Oxygen Biotherapeutics, Inc. today announced it has received a $2.075 million, two-year grant from the U.S. Army to study the Company's proprietary Oxycyte PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury.

2 Mar 2011

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin in combination with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma patients.

1 Mar 2011

Nile plans to develop novel therapeutics for ADHF

Nile Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, announced plans to pursue a new indication in the field of heart failure.

1 Mar 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

Positive results from Trius torezolid Phase 1 lung study

Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into the lung for potential use to treat lung infections. In this study a 200 mg dose of torezolid phosphate was administered orally once-daily for three days to healthy adult volunteers. The trial achieved its primary goal of establishing the steady-state plasma pharmacokinetics and distribution of active drug into epithelial lining fluid (ELF).

28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Pharmacokinetics News and Research

Further Reading

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

KaloBios commences KB004 Phase 1 trial in patients with leukemia

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis

Anavex to commence phase I clinical trial in Alzheimer’s disease

Arena fourth quarter net loss decreases to $28.2 million

Inhibitex fourth quarter net loss increases to $7.0 million

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

NorthShore receives $1.5 million gift to establish center for the study of complex diseases

Cancer patients' willingness to undergo tests bodes well for future of personalized medicine

EC grants marketing authorization for InterMune's Esbriet to treat IPF

Oxygen Biotherapeutics receives U.S. Army grant for studies of Oxycyte

U.S. Army awards Oxygen Biotherapeutics two-year grant to study Oxycyte PFC emulsion against TBI

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Nile plans to develop novel therapeutics for ADHF

TCD announces first patient treated in its TCD-717 Phase I trial

Positive results from Trius torezolid Phase 1 lung study

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Industry Focus - Biopharma eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News